{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:42:33Z","timestamp":1770961353089,"version":"3.50.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2015,3,4]]},"DOI":"10.1517\/14740338.2015.1009035","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T07:09:00Z","timestamp":1422947340000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C"],"prefix":"10.1517","volume":"14","author":[{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis385"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.12505"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26903"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.035"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.013"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.022"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014.61:373-95; Available from: http:\/\/files.easl.eu\/easl-recommendations-on-treatment-of-hepatitis-C\/index.html [Last accessed 29 September 2014]","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.12.34"},{"key":"e_1_3_2_12_1","unstructured":"Kirby B Gordi T Symonds WT et al. Population pharmacokinetics of Sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected subjects. 64th annual meeting of the american association for the study of liver diseases; 1-5 November 2013; Washington DC"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S44375"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.04.018"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014534194"},{"key":"e_1_3_2_16_1","first-page":"91A","article-title":"Ledipasvir\/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study","volume":"60","author":"Flamm SL","year":"2014","unstructured":"Flamm SL, Everson GT, Charlton M, et al. Ledipasvir\/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60:91A","journal-title":"Hepatology"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60070-2"},{"issue":"1","key":"e_1_3_2_22_1","first-page":"314A","article-title":"Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation","volume":"58","author":"Curry MP","year":"2013","unstructured":"Curry MP, Forns X, Chung RT, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013;58(Suppl 1):314A","journal-title":"Hepatology"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"e_1_3_2_24_1","first-page":"58A","article-title":"Safety and efficacy of treatment with sofosbuvir+GS-5816\u00b1ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1-6 HCV infection","volume":"60","author":"Tran TT","year":"2014","unstructured":"Tran TT, Morgan TR, Thuluvath PJ, et al. Safety and efficacy of treatment with sofosbuvir+GS-5816\u00b1ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1-6 HCV infection. Hepatology 2014;60:58A","journal-title":"Hepatology"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.007"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_3_2_29_1","first-page":"239A","article-title":"An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir\/sofosbuvir with or without ribavirin","volume":"60","author":"Bourli\u00e8re M","year":"2014","unstructured":"Bourli\u00e8re M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir\/sofosbuvir with or without ribavirin. Hepatology 2014;60:239A","journal-title":"Hepatology"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60008-8"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_3_2_32_1","first-page":"660A","article-title":"Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + ribavirin (RBV) in Patients with Genotype 1: interim Results of a Prospective, Observational Study","volume":"60","author":"Sulkowski M","year":"2014","unstructured":"Sulkowski M, Vargas H, Di Bisceglie A, et al. Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + ribavirin (RBV) in Patients with Genotype 1: interim Results of a Prospective, Observational Study. Hepatology 2014;60:660A","journal-title":"Hepatology"},{"key":"e_1_3_2_33_1","unstructured":"Morelli G et al. Open-label study to evaluate safety tolerability and efficacy of telaprevir in combination with sofosbuvir in treatment-na\u00efve patients with genotype 1 hepatitis c virus infection [poster 63169]. AASLD\/EASL Special Conference; 12-13 September 2014; New York"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.06.004"},{"key":"e_1_3_2_36_1","unstructured":"Sovaldi\u00ae label (Sofosbuvir). Package Insert. 2014"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00310-6"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.11.015"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.025"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31773"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21090"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.06.029"},{"key":"e_1_3_2_43_1","unstructured":"Mathias A Cornpropst M Clemons D et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressant cyclosporine A or tacrolymus in healthy volunteers. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1-5 November 2013; Washington DC"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60064-7"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01517.x"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.06.005"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14740338.2015.1009035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:07:28Z","timestamp":1770386848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14740338.2015.1009035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3,4]]}},"alternative-id":["10.1517\/14740338.2015.1009035"],"URL":"https:\/\/doi.org\/10.1517\/14740338.2015.1009035","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}